logo

Are researchers studying an antacid's effect on COVID-19?

Monday, May 11, 2020
By Remaya Campbell
YES

Researchers from the Feinstein Institutes for Medical Research in New York and Columbia University Medical Center have enrolled at least 150 participants in a study testing the effects of famotidine (the active ingredient in the common heartburn drug Pepcid) on COVID-19 patients. The study launched in the U.S. after molecular modeling and positive reports from China suggested that famotidine could serve as a possible inhibitor to the virus that causes COVID-19.

In May 2020, preliminary findings were released showing that the use of famotidine on hospitalized COVID-19 patients was associated with reduced need for breathing machines and reduced risks of death. The study is not yet peer-reviewed and clinical trials remain ongoing.

This fact brief is responsive to conversations such as this one.
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
facebook
twitter
email
email